InMed Pharmaceuticals (INM) Common Equity (2019 - 2026)

InMed Pharmaceuticals has reported Common Equity for 8 years, with the latest figure at $6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 1.85% year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (down 1.85% YoY), and the FY2025 full-year result was $13.4 million, up 45.93% from the prior year.
• Common Equity for Q1 2026 stood at $6.9 million, down from $9.6 million in the prior quarter.
• The five-year high for Common Equity was $14.3 million in Q4 2022, with the low at -$9.6 million in Q3 2023.
• Historically, Common Equity has averaged $9.2 million across 5 years, with a median of $10.9 million in 2022.
• Annual changes were most pronounced in 2023 — Common Equity sank 187.01% — and 2024, when it surged 187.65%.
• InMed Pharmaceuticals' Common Equity stood at $14.3 million in 2022, then declined by 10.9% to $12.8 million in 2023, then slumped by 51.6% to $6.2 million in 2024, then surged by 55.09% to $9.6 million in 2025, then decreased by 28.12% to $6.9 million in 2026.
• The last three Common Equity figures came in at $6.9 million (Q1 2026), $9.6 million (Q4 2025), and $11.6 million (Q3 2025), per Business Quant data.